US Medical Affairs, Solid Tumor Strategy Summer Intern
Genmab
Summary
We are currently seeking a US Medical Affairs, Solid Tumor Strategy Summer Intern who will gain hands-on, real-world experience in the pharmaceutical industry. As an intern, you will work on projects that improve your leadership, problem-solving, and critical thinking skills, while gaining cross-functional exposure and networking opportunities. You will have a focus in US market Medical Affairs H&N cancer strategy, and work with knowledgeable mentors to develop skills to build a strong career foundation.
Job description
Job Overview
We are currently seeking a US Medical Affairs, Solid Tumor Strategy Summer Intern who will gain hands-on, real-world experience in the pharmaceutical industry. As an intern, you will work on projects that improve your leadership, problem-solving, and critical thinking skills, while gaining cross-functional exposure and networking opportunities. You will have a focus in US market Medical Affairs H&N cancer strategy, and work with knowledgeable mentors to develop skills to build a strong career foundation.
What You'll Do
- Gain exposure to medical affairs strategies and tactics in the US market that are intended to ensure the safe and effective use of our medicines as well as increasing the awareness of treatment options for healthcare professionals and patients
- Learn the latest trends, developments, and competitive landscape in the US market, particularly within H&N cancers, and how to use this knowledge to inform and adapt to the US Medical Affairs strategy
- Participate in the planning and execution of a Journal Club Presentation with opportunities to perform scientific publication intelligence, analyze key competitors' publications, communicate/present findings to internal teams, and lead discussions on strategic implications
- Gain exposure to external thought leader engagement, exercise strategic thinking, and gain project management experience
- Use creative problem-solving skillsets, develop new ideas and insights, including takeaways about yourself as a leader and individual contributor
Required Qualifications, Capabilities And Skills
- Currently in later years of pursuing an advanced degree in the life sciences field (e.g., PharmD, PhD)
- Proficient with scientific/medical data and nomenclature
- Has a desire to become proficient in effectively communicating complex scientific information to various stakeholders
- Able to work independently, proactively, and part of a group, with curiosity and flexibility
- Excellent written and verbal communication skills
- Possess a "can-do" approach and courage to speak your voice and suggest innovative ideas
- Proficient with Microsoft applications (Word, Excel, PowerPoint, Outlook, Teams)
Preferred Qualifications, Capabilities And Skills
- Demonstrated leadership in campus/community activities
Requirements
- Currently in later years of pursuing an advanced degree in the life sciences field (e.g., PharmD, PhD)
- Proficient with scientific/medical data and nomenclature
- Has a desire to become proficient in effectively communicating complex scientific information to various stakeholders
- Able to work independently, proactively, and part of a group, with curiosity and flexibility
- Excellent written and verbal communication skills
- Possess a "can-do" approach and courage to speak your voice and suggest innovative ideas
- Proficient with Microsoft applications (Word, Excel, PowerPoint, Outlook, Teams)
- Demonstrated leadership in campus/community activities
Company overview
Genmab is a leading international biotechnology company headquartered in Copenhagen, Denmark, specializing in the development and commercialization of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has established itself as a pioneer in antibody technology with its proprietary DuoBody, HexaBody, and DuoHexaBody platforms. Genmab's innovative approach focuses on creating next-generation antibody-based therapies that target specific cancer cells while minimizing damage to healthy tissues. The company has several marketed products including DARZALEX (daratumumab) for multiple myeloma, which has become a cornerstone treatment in hematological malignancies. Genmab's pipeline includes numerous clinical-stage candidates targeting various cancers, leveraging its expertise in antibody engineering to develop novel immunotherapies. The company collaborates with major pharmaceutical partners worldwide and maintains a strong commitment to advancing cancer treatment through cutting-edge science and patient-focused innovation.